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Abstract
Background: Antibodies against carbamylated proteins (anti-CarP) have been recently identified in the sera of patients
with rheumatoid arthritis (RA). The objective of the study was to evaluate the prevalence, sensitivity and specificity of anti-
CarP compared to anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF), replicating the existing data in
a large cohort of Italian patients with RA and extending the evaluation to other autoimmune rheumatic diseases (AIRDs).
Methods: Serum samples (n = 607) from 309 patients with RA, 200 disease controls and 98 normal healthy subjects
(NHS) were evaluated. Anti-CarP were detected using carbamylated fetal calf serum as the antigen. ACPAs were detected
using second-generation ELISA and IgM RF was assessed as part of routine analysis.
Results: Anti-CarP antibodies were detected in 117 patients with RA (34.4%), ACPA in 190 patients (61.4%) and RF in
202 patients (65.3%). Two (2.04%) of the NHS were positive for anti-CarP, one NHS (1.02%) was positive for ACPA and
three NHS were positive for RF (3.06%). Among disease controls, anti-CarP antibodies were detected in 33 patients
(16.5%), ACPA in 29 patients (14.5%) and RF in 64 patients (32%). In particular, 16.8% of patients with systemic lupus
erythematosus and 31.1% of patients with Sjögren syndrome were positive for anti-CarP. The sensitivity of anti-CarP,
ACPA and RF was 46.8%, 61.8% and 64.4%, respectively and specificity was 91.95%, 89.93% and 76.51%, respectively.
Conclusions: The present study extends the knowledge of anti-CarP antibodies, confirming previous data on the
diagnostic accuracy of anti-CarP in RA in a large cohort of Italian patients. Anti-CarP antibodies demonstrated relatively
low sensitivity and slightly higher specificity compared to ACPA and RF. Even if predominantly present in RA, anti-CarP
was detected in a variable percentage of patients with other autoimmune rheumatic diseases and their generation
could be attributed to the inflammatory status; the clinical relevance of anti-CarP antibodies in these latter patients
should be further determined.
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Background
The discovery of autoantibodies in patients with RA facili-
tated the subgrouping of these patients for more accurate
therapeutic management, resulting in more efficient dis-
ease control [1]. Beside the well-known rheumatoid factor
(RF), anti-citrullinated protein antibodies (ACPA) have
been reported to be a very useful diagnostic and prognos-
tic marker of RA [2]. ACPA have remarkable sensitivity
for this disease, with high predictive value for RA develop-
ment and severity [2, 3]. The importance of ACPA in RA
was highlighted by the inclusion of ACPA status in the
2010 classification criteria for RA by allowing the division
of patients with RA into two major subsets: ACPA-
positive and ACPA-negative [4].
Although ACPA have an important role in the diagnosis
of RA, there is still a continuous demand for new bio-
markers to further improve the early diagnosis of RA and
especially its seronegative subgroup [5]. Recently, a new
autoantibody system recognising antibodies against carba-
mylated proteins (anti-CarP) has been described [6] but
has not yet been implemented for commercial use.
Initially, Shi et al. identified homocitrulline as the main
aminoacid involved in the binding of autoantibodies in
seronegative patients with RA [7]. Carbamylation is a
chemical reaction mediated by cyanate that modifies lysine
residues [5]. Normally the level of cyanate is in equilibrium
with urea but specific conditions like inflammation
can warp this equilibrium through a myeloperoxidase-
dependent mechanism [8, 9]. This leads to the local
increase of cyanate levels, thus empowering the degree
of carbamylation [10].
Although the high resemblance in structure between
citrulline and homocitrulline, inhibition and cohort
studies have demonstrated that ACPA and anti-CarP are
different and independent antibody subsets that do not
cross-react with each other [4, 5]. Unlike ACPA, the
presence of anti-CarP has not been associated with
HLA-shared epitope (SE) and/or smoking [11]. An inter-
esting finding was the presence of anti-CarP in ACPA-
negative patients with RA and their association with in-
creased disease activity [12, 13] and severe joint damage
[13, 14]. Moreover, anti-CarP have been detected in pa-
tients with arthralgia and their presence has been inde-
pendently associated with the risk of developing RA [15].
In addition, anti-CarP are present in serum from patients
with RA many years before the clinical appearance of the
disease [14, 16, 17] and have also been identified in
healthy first-degree relatives of patients with RA [18].
Recently, Shi et al. investigated the diagnostic perform-
ance of anti-CarP in RA in a large cohort of patients with
early arthritis and demonstrated that these antibodies are
predominantly detected in RA, but that a small percentage
of patients with almost all forms of early arthritis
were also anti-CarP-positive [19]. Considering the high
prognostic and predictive value that anti-CarP have dem-
onstrated in patients with RA, the aim of this study was to
evaluate their prevalence, sensitivity and specificity in a
large monocentric cohort of patients with RA compared
to other autoimmune rheumatic diseases (AIRDs).
Methods
Patient populations
We evaluated a total of 607 frozen stored serum samples
from 309 patients with established RA diagnosed according
to the 2010 American College of Rheumatology (ACR)/
European League Against Rheumatism (EULAR) criteria,
and 200 unselected patients with other diseases [systemic
lupus erythematosus (SLE), Sjögren syndrome (SS), sys-
temic sclerosis (SSc), and postmenopausal osteoporosis
(OP)], who were not matched by gender or age with the
RA group, and who were attending outpatient clinics at
Sapienza University of Rome. Serum samples from 98 un-
selected normal healthy subjects (NHS) were also tested.
Anti-CarP antibody assays
Anti-CarP antibodies were detected by a modified solid
phase “home-made” ELISA as described by Shi et al., with
some modifications [20] using carbamylated fetal calf
serum (FCS) as the antigen. In brief, Nunc Maxisorp plates
(Thermo Scientific, Whaltam, MA, USA) were coated over-
night at +4 ° C with non-modified FCS and Ca-FCS (10 μg/
ml in carbonate bicarbonate buffer). After washing the
plates were blocked with phosphate-buffered saline (PBS)
1% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis,
MO, USA) for 6 h at +4 ° C. Subsequently, the wells were
incubated with serum from patients, diluted 1/50 in PBS/
0.05% tween/BSA 1% overnight at +4 ° C. After four washes
the plates were incubated for 2 h at room temperature
(RT) with goat polyclonal antihuman IgG alkaline phos-
phatase conjugated antibodies (Sigma-Aldrich, St. Louis,
MO, USA) diluted at 1:1000 in PBS/0.05% tween/BSA 1%.
After four washes a solution of paranitrophenyl phosphate
tablets in ethanolamine was used for the enzyme reaction
and the plates were read at a 405 nm wavelength after
30 minutes at RT. All assays were performed in duplicate
and the absorbance of control wells (unmodified FCS) was
subtracted to account for non-specific binding. The levels
were determined in arbitrary units per millilitre (AU/ml)
using a standard curve. The cutoff for anti-CarP antibody
ELISA was established as the mean plus three times the
standard deviation (SD) of the healthy control.
Anti-CCP and RF antibody assays
ACPA were detected using a second-generation ELISA
(anti-CCP) kit (Delta Biologicals, Italy) while IgM RF
was determined as part of routine analysis by immuno-
nephelometry (Behering, Marburg, Germany) according
to the manufacturers’ instructions.
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Statistical analysis
The diagnostic performance of ACPA, RF and anti-CarP
antibodies assays was determined by receiver operating
characteristic (ROC) curve analysis, by plotting sensi-
tivity (%) against 100-specificity (%) at different cutoff
values. Diagnostic sensitivity was compared at cutoff
levels corresponding to 95% specificity. Dunn’s mul-
tiple comparison test was used to compare the levels of
anti-CarP antibodies between the different diagnoses
and the chi-square test was used to compare the
percentage of the patients with other rheumatic condi-
tions who were positive for the these antibodies. P
values <0.05 were considered statistically significant.
Data analysis was performed using SPSS version 20
(SPSS Inc., Chicago, IL, USA).
Results
We analysed serum from 309 patients with RA (mean
age 55.4 ± 13.8 years), who had a mean disease duration
of 107 ± 97.6 months; 238 (77%) were female, and 167
(54%) were smokers. Table 1 shows the characteristic of
patients with RA and the control groups.
Anti-CarP, anti-CCP and RF in Patients with RA and
controls
The overall prevalence of anti-CarP, RF, and anti-CCP in
patients with RA, disease controls and healthy subjects
is shown in Table 2.
The prevalence of anti-CarP antibodies was signifi-
cantly higher in patients with RA compared to healthy
controls (p = 0.00005) and non-RA disease (p < 0.00001
for SLE, SSc and OP) but not compared to SS (p = 0.05).
Even when considering the disease controls as a whole
group, the prevalence of anti-CarP antibodies was still
significantly higher in patients with RA (p < 0.00001).
Figure 1 shows the distribution of anti-CarP, ACPA and
IgM-RF in patients with RA (Fig. 1a) and non-RA dis-
ease (Fig. 1b); most of the patients with RA were positive
for all three antibodies tested (27% of patients) or as
combination of two antibodies. Conversely, among the
non-RA disease controls only two patients with SLE had
double positivity for anti-CarP and ACPA and other two
were triple-positive and were diagnosed as having Rhu-
pus; moreover, two patients with SS were triple-positive
and one of them was diagnosed as having RA-associated
SS. Interestingly, in the subset of seronegative patients
with RA, 29% of these patients (25 out of 87) had anti-
CarP antibodies (Fig. 1c and d).
When evaluating the association between RA subsets
according to antibody positivity and cigarette smoking
there was an association with the presence and titre of
ACPA (p = 0.001) but not with anti-CarP positivity or
with RF (Table 3). None of the autoantibodies correlated
with disease activity as measured by disease activity
score in 28 joints (DAS 28).
The AUC from ROC analysis (Fig. 2) was 0.678 (95%
CI 0.636–0.720) for anti-CarP, 0.858 (95% CI 0.830–
0.887) for ACPAs and 0.796 (95% CI 0.761–0.831) for
RF. Among the three antibodies studied, anti-CarP anti-
bodies had the highest specificity but relatively low sen-
sitivity (91.9 and 46.8, respectively). Table 4 summarizes
the diagnostic performance of anti-CarP compared to
ACPA and RF.
Anti-CarP serum levels in patients with RA and in
controls are shown in Fig. 3. When comparing the anti-
CarP titre in positive patients we noticed that the levels
were significantly higher in patients with RA compared
to non-RA conditions (p < 0.05 for all conditions)
(Fig. 3). Nevertheless, high levels of anti-CarP anti-
bodies were detected even in the few patients with SLE
and SS, although these levels were never as high as the
levels of anti-CarP antibodies in the patients with RA
(Fig. 3). Anti-CarP, ACPA and IgM-RF were not statisti-
cally different among the patients with non-RA disease
(p > 0.05 for all).
Discussion
In recent years, the importance of early diagnosis and
treatment toward more efficient control of the disease,
Table 1 Characteristic of study participants
Disease
(number of patients)
Age (years)
(mean + SD)
Female
n, (%)
Smokers
n, (%)
RA (309) 55.4 + 13.8 238 (77) 167 (54)
SLE (83) 42.8 + 11.3 57 (68.6) 34 (40.9)
SSC (51) 50.4 + 12.1 51 (100) 10 (19.6)
SS (45) 53.3 + 13.1 30 (66.6) 26 (48.1)
OP (21) 66.1 + 7.2 21 (100) 2 (9.5)
HS (98) 53.1 + 10.4 73 (74.5) 43 (43.9)
RA rheumatoid arthritis, SLE systemic lupus erythematosus, SS Sjögren
syndrome, SSc systemic sclerosis, OP osteoporosis, HS healthy subjects
Table 2 Prevalence of anti-CarP, ACPA and RF in patients with
RA, disease controls and healthy subjects
Disease
(number of patients)
Anti-CarP positive,
n, (%)
ACPA positive,
n, (%)
RF positive,
n, (%)
RA (309) 117 (34.4) 190 (61.4) 202 (65.3)
NHS (98) 2 (2.04) 1 (1.02) 3 (3.06)
SLE (83) 14 (16.8) 15 (18.07) 19 (22.8)
SS (45) 14 (31.1) 11 (24.4) 23 (51.1)
SSc (51) 3 (5.8) 1 (1.9) 18 (35.2)
OP (21) 2 (9.5) 2 (9.5) 4 (19.04)
Anti-CarP anti-carbamylated proteins antibodies, ACPA anti-citrullinated peptides
antibodies, RF rheumatoid factor, RA rheumatoid arthritis, NHS normal healthy
subjects, SLE systemic lupus erythematosus, SS Sjögren syndrome, SSc systemic
sclerosis, OP osteoporosis
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Fig. 1 Distribution of antibodies against carbamylated proteins (anti-CarP), anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF)
in patients with rheumatoid arthritis (RA) and disease controls. a–b Venn diagram showing the relationship between anti-CarP antibodies, ACPA
and IgM RF in patients with RA (a) and other conditions (non-RA) (b). c Anti-CarP positivity in the whole RA population and double-negative
patients with RA. d Distribution of single, double and triple positivity for anti-CarP, ACPA and RF in patients with RA
Table 3 Association between smoking and different RA subsets according to the presence/absence of anti-CarP antibodies, ACPA and RF
Smoking
Disease subset Patients, n Never smoked, n (%) Ever smoked, n (%) 95% CI P value
Anti-CarP (−)/ACPA (−)/RF (−) 62 31 (50%) 31 (50%) −2.2–2.2 ns
Anti-CarP (+)/ACPA (+)/RF (+) 82 32 (39%) 50 (61%) 19.7–24.7 0.0001
Anti-CarP (−)/ACPA (+)/RF (+) 89 40 (45%) 49 (55%) 7.7–12.2 0.0001
Anti-CarP (+)/ACPA (−)/RF (−) 26 14 (53.8%) 12 (46.2%) −4.2–0.2 ns
Anti-CarP (−)/ACPA (+)/RF (−) 15 6 (40%) 9 (60%) 0.7–5.2 0.02
Anti-CarP (−)/ACPA (−)/RF (+) 26 14 (53.8%) 12 (46.2%) −4.2–0.2 ns
Anti-CarP (+)/ACPA (+)/RF (−) 4 2 (50%) 2 (50%) −2.2–2.2 ns
Anti-CarP (+)/ACPA (−)/RF (+) 5 3 (60%) 2 (40%) −3.2–1.2 ns
RA rheumatoid arthritis, Anti-CarP antibodies against carbamylated proteins, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, ns not significant
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less joint damage and a better outcome has been clearly
stated. For this reason, research has mostly focused on
identifying biomarkers and specific laboratory tests to
be applied in the early detection of RA [1]. The present
study analyses prevalence, sensitivity and specificity of
anti-CarP antibodies, replicating previously published
data in a large, single-centre cohort of Italian patients
with RA compared to healthy controls and patients
with other AIRDs. For the first time we investigated in
a single study the positivity of anti-CarP, even including
patients with different systemic AIRDs, which are
known to be associated with the production of several
autoantibodies.
In this study we confirmed the data on anti-CarP
showing the presence of these antibodies in a significant
number of patients with RA. Actually, 15 patients were
single-positive for ACPA and 26 were single-positive for
anti-CarP, confirming the lack of cross-reactivity be-
tween anti-citrullinated and anti-homocitrullinated pro-
teins as previously described [6]. Isolated anti-CarP
positivity was detected in about one third of patients
with RA who were seronegative for ACPA and RF.
The major advantage of simultaneous or alternative
detection of a wide range of biomarkers consists in a
Fig. 2 Receiver operating characteristic curve for antibodies against carbamylated proteins (anti-CarP), anti-citrullinated protein antibodies (ACPA)
and rheumatoid factor (RF)
Table 4 Diagnostic performance of anti-CarP antibodies, ACPA
and RF
Sensitivity (95% CI) Specificity (95% CI) LR PPV NPV
Anti-CarP 46.8 (41.50–52.54) 91.95 (82.25–94.77) 4.581 88% 60%
ACPA 61.8 (56.14–67.25) 89.93 (85.94–93.10) 6.14 85% 62%
RF 64.4 (58.78–69.74) 76.51 (71.28–81.21) 2.742 80% 69%
Anti-CarP antibodies against carbamylated proteins, ACPA anti-citrullinated
protein antibodies, RF rheumatoid factor, LR likelihood ratio, PPV positive
predictive value, NPV negative predictive value
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much detailed classification of RA subtypes, increasing
the sensitivity of RA diagnosis [2, 5]. As suggested by
the results of previous research [6, 7], in this study we
were able to identify different immunological RA subsets
based on the presence and/or absence of the three auto-
antibodies studied (anti-CarP, ACPA and RF) opening a
new window of opportunity to more precise disease clas-
sification and treatment. When comparing the findings
of the present study with previous results, there is a
difference in the percentage of triple positivity for anti-
CarP, ACPA and RF: indeed, the percentage of triple-
positive patients is lower among patients in the Norfolk
Arthritis Register and higher in the early arthritis Leiden
cohort compared to the present cohort of Italian pa-
tients with RA [12, 19]; this discrepancy could result
from the different genetic background of the populations
studied. Moreover, unlike the results of a longitudinal
study, reporting higher disease activity over time in anti-
CarP-positive patients [12], the findings of our cross-
sectional analysis agree with the lack of association with
disease activity reported by others [13].
Unlike citrullination - that is an enzimatically medi-
ated reaction - carbamylation is a chemical reaction that
occurs in the presence of a reactive metabolite (cyanate)
[6]. Theoretically, every protein can be carbamylated in
vivo but the probability of a protein undergoing such
modification depends on various parameters such as the
number and accessibility of lysine and arginine amino
groups and the protein lifespan [7]. As carbamylation is
an almost irreversible reaction, it is more likeky to affect
long-lived proteins as they may have acquired homoci-
trulline residues over time [7]. Taken together, these data
suggest that even the antibodies produced by these post-
translational modification reactions may differ in terms
of sensitivity and specificity. Thus, in the present study,
we compared the diagnostic performance of anti-CarP
antibodies, ACPAs and RF in a large monocentric cohort
of patients with RA compared to disease and healthy
controls with different AIRDs.
As already mentioned, anti-CarP antibodies were
present in a significant percentage in seronegative and
seropositive patients with RA. Beside patients with RA,
anti-CarP antibodies were present in a small number of
patients with SLE and SS; less than one third of these
patients also displayed ACPA positivity. These results
can be partially attributed to erosive joint disease de-
scribed in a small percentage of patients with SLE [21];
besides, carbamylation can be enhanced in patients with
kidney involvement or in those with active inflammatory
status [8]. Similarly, a clear link between antibody
production and the degree of inflammation has been
shown in patients with SS, as the activity of circulating
myeloperoxidase (MPO), which catalyzes the production
of cyanate from thiocyanate, seems to be significantly
increased [20]. Two studies investigated anti-CarP in
patients with SLE and with SS [20, 21]. The detection of
a subset of anti-CarP-positive subjects among patients
with SLE or SS and joint involvement suggests the possi-
bility of that anti-CarP might serve as a serological
marker for erosive arthritis in AIRDs other than RA.
However, the clinical and prognostic relevance of these
autoantibodies in patients with non-RA needs to be fur-
ther elucidated.
In diagnostic performance, anti-CarP antibodies had
slightly higher specificity but relatively lower sensitivity
when compared to ACPA and IgM-RF. On the other
hand, the AUC for anti-CarP antibodies in the whole
population was 0.678, whereas in the seronegative group
Fig. 3 Antibodies against carbamylated proteins (anti-CarP) in serum from patients and controls. Horizontal line corresponds to cutoff value:
*p < 0.0005 for rheumatoid arthritis (RA) vs normal healthy subjects (NHS) and patients with osteoporosis (OP); **p = 0.03 for RA vs systemic lupus
erythematosus (SLE); ***p = 0.04 for RA vs Sjögren syndrome (SS); ****p = 0.004 RA vs systemic sclerosis (SSc); §p = 0.00001 for SLE vs NHS; §§p = 0.002
for SLE vs SSc; §§§p = 0.05 for SLE vs OP; #p = 0.00001 for SS vs NHS and SS vs SSc; †p = 0.03 for SSc vs NHS; ††p = 0.004 for SSc vs OP
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it was only 0.565. These data suggest an additional role
of anti-CarP positivity in the diagnosis of RA, in agree-
ment with previous studies reporting the presence and
prognostic value of anti-CarP antibodies in the RA sero-
negative subgroup, and correlation with joint destruction
[7, 12, 13, 15]. The diagnosis of RA is mostly clinical,
and it is supported by serological data. Nonetheless,
as we are moving toward the identification of RA in
its early phases, biomarkers could help in stratifying
subjects at risk of developing overt disease even in
pre-clinical phases [4, 5].
Conclusions
In conclusion, the results of the present study extend
the knowledge on anti-CarP providing updated data on
prevalence, sensitivity and specificity on a large cohort
of Italian patients. Moreover, we confirm that anti-CarP
antibodies and ACPA are not always present simultan-
eously. The positivity of these antibodies in patients with
non-RA autoimmune rheumatic disease can be attributed
to the inflammatory status and should be addressed in
further studies in order to better understand their role
in autoimmune diseases.
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